Anti-UBE2C抗体(ab12290)
Key features and details
- Rabbit polyclonal to UBE2C
- Suitable for: ICC/IF, WB
- Reacts with: Human
- Isotype: IgG
选择批间可重复性更高的重组抗体
- 研究可靠 —— 各批次间结果一致且可重复
- 长期批量供应 —— 采用重组技术，可实现快速生产
- 首次实验即可成功 —— 经过大量验证确认了特异性
- 符合伦理标准 —— 产品不含动物成分
概述
-
产品名称
Anti-UBE2C抗体
参阅全部 UBE2C 一抗 -
描述
兔多克隆抗体to UBE2C -
宿主
Rabbit -
特异性
This antibody recognises a band of the correct size (20 kDa) in Hela, A431, Jurkat, Jurkat nuclear and 293 lysates. -
经测试应用
适用于: ICC/IF, WBmore details -
种属反应性
与反应: Human
预测可用于: Mouse
-
免疫原
Synthetic peptide corresponding to Human UBE2C aa 150 to the C-terminus (C terminal) conjugated to keyhole limpet haemocyanin.
(Peptide available asab12304) -
阳性对照
- This antibody gave a positive signal in the following whole cell lysates: HeLa; Jurkat; A431; HEK293. It also gave a positive signal in Jurkat nuclear extract.
-
常规说明
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Add glycerol to a final volume of 50% for extra stability and aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
存储溶液
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 98.98% PBS, 1% BSA
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help. -
Concentration information loading... -
纯度
Immunogen affinity purified -
克隆
多克隆 -
同种型
IgG -
研究领域
相关产品
-
Compatible Secondaries
-
Isotype control
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab12290于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度；实际最佳的稀释度/浓度应由使用者检定。
| 应用 | Ab评论 | 说明 |
|---|---|---|
| ICC/IF |
Use a concentration of 1 µg/ml.
|
|
| WB |
1/500. Predicted molecular weight: 20 kDa.
|
| 说明 |
|---|
|
ICC/IF
Use a concentration of 1 µg/ml. |
|
WB
1/500. Predicted molecular weight: 20 kDa. |
靶标
-
功能
Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'- and 'Lys-48'-linked polyubiquitination. Acts as an essential factor of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated ubiquitin ligase that controls progression through mitosis. Acts by initiating 'Lys-11'-linked polyubiquitin chains on APC/C substrates, leading to the degradation of APC/C substrates by the proteasome and promoting mitotic exit. -
通路
Protein modification; protein ubiquitination. -
序列相似性
Belongs to the ubiquitin-conjugating enzyme family. -
翻译后修饰
Autoubiquitinated by the APC/C complex, leading to its degradation by the proteasome. Its degradation plays a central role in APC/C regulation, allowing cyclin-A accumulation before S phase entry. APC/C substrates inhibit the autoubiquitination of UBE2C/UBCH10 but not its E2 function, hence APC/C remaining active until its substrates have been destroyed. - Information by UniProt
-
数据库链接
- Entrez Gene: 11065 Human
- Entrez Gene: 68612 Mouse
- Omim: 605574 Human
- SwissProt: O00762 Human
- SwissProt: Q9D1C1 Mouse
- Unigene: 93002 Human
- Unigene: 89830 Mouse
-
别名
- Cyclin selective ubiquitin carrier protein antibody
- dJ447F3.2 antibody
- Mitotic specific ubiquitin conjugating enzyme antibody
see all
图片
-
Western blot - Anti-UBE2C antibody (ab12290)All lanes : Anti-UBE2C antibody (ab12290) at 1/1000 dilution
Lane 1 : Wild-type HeLa cell lysate
Lane 2 : UBE2C knockout HeLa cell lysate
Lane 3 : WI-38 cell lysate
Lane 4 : K-562 (Human chronic myelogenous leukemia lymphoblast cell line ) whole cell lysate
Lane 5 : SW480 cell lysate
Lane 6 : CACO2 cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 20 kDa
Observed band size: 20 kDaFalse colour image of Western blot: Anti-UBE2C antibody staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab12290 was shown to bind specifically to UBE2C. A band was observed at 20 kDa in wild-type HeLa cell lysates with no signal observed at this size in UBE2C knockout cell line ab265032 (knockout cell lysate ab257775). To generate this image, wild-type and UBE2C knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.
-
Western blot - Anti-UBE2C antibody (ab12290)All lanes : Anti-UBE2C antibody (ab12290) at 1 µg/ml
Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
Lane 2 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate
Lane 3 : Jurkat nuclear extract lysate (ab14844)
Lane 4 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate
Lane 5 : HEK293 Human embryonic kidney cell line Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : IRDye 680 Conjugated Goat Anti-Rabbit IgG (H+L) at 1/10000 dilution
Predicted band size: 20 kDa
Observed band size: 20 kDa
Additional bands at: 55 kDa, 70 kDa. We are unsure as to the identity of these extra bands. -
Immunocytochemistry/ Immunofluorescence - Anti-UBE2C antibody (ab12290)ICC/IF image of ab12290 stained human HEK 293 cells. The cells were methanol fixed (5 min), permabilised in 0.1% PBS-Tween (20 min) and incubated with the antibody (ab12290, 1µg/ml) for 1h at room temperature. 1%BSA / 10% normal goat serum / 0.3M glycine was used to block non-specific protein-protein interactions. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red). DAPI was used to stain the cell nuclei (blue). This antibody also gave a positive IF result in HepG2 and MCF7 cells.
实验方案
数据表及文件
-
SDS download
-
Datasheet download
文献 (10)
ab12290 被引用在 10 文献中.
- Cao JZ et al. UBE2C promotes the progression of pancreatic cancer and glycolytic activity via EGFR stabilization-mediated PI3K-Akt pathway activation. J Gastrointest Oncol 13:1444-1453 (2022). PubMed: 35837197
- Zhu J et al. Delineating the dynamic evolution from preneoplasia to invasive lung adenocarcinoma by integrating single-cell RNA sequencing and spatial transcriptomics. Exp Mol Med 54:2060-2076 (2022). PubMed: 36434043
- Dai J et al. LncRNA MALAT1 Regulating Lung Carcinoma Progression via the miR-491-5p/UBE2C Axis. Pathol Oncol Res 27:610159 (2021). PubMed: 34257576
- Zeng J et al. Derlin-1 exhibits oncogenic activities and indicates an unfavorable prognosis in breast cancer. Cell Biol Int 44:593-602 (2020). PubMed: 31670413
- Lu J et al. Antitumor effects of hsa-miR661-3p on non-small cell lung cancer in vivo and in vitro. Oncol Rep 41:2987-2996 (2019). PubMed: 30896844
- Jin D et al. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC. Theranostics 9:2036-2055 (2019). PubMed: 31037155
- Guo J et al. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. EBioMedicine 35:204-221 (2018). PubMed: 30146342
- Wang W et al. A novel molecular and clinical staging model to predict survival for patients with esophageal squamous cell carcinoma. Oncotarget 7:63526-63536 (2016). PubMed: 27556859
- García-Escudero R et al. Gene expression profiling of mouse p53-deficient epidermal carcinoma defines molecular determinants of human cancer malignancy. Mol Cancer 9:193 (2010). IHC-P ; Human . PubMed: 20630075
- Lin J et al. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia 8:1062-71 (2006). PubMed: 17217624